Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bryan Goldman

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
The Journal of Urology|April 18, 2009
A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219)Ralph W deVere White, Primo N Lara, Bryan Goldman, et al.
Diabetes, Obesity & Metabolism|September 13, 2021
Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight lossSean Wharton, Salvatore Calanna, Melanie Davies, et al.
Diabetes Care|November 26, 2025
Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS StudySilva Arslanian, Inge Gies, Bryan Goldman, et al.
Cancer|July 22, 2014
Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727)Philip A Philip, Bryan Goldman, Ramesh K Ramanathan, et al.
Obesity (Silver Spring, Md.)|May 23, 2020
Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5Robert F Kushner, Salvatore Calanna, Melanie Davies, et al.
Journal of the American College of Cardiology|March 14, 2020
Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart FailureSteven P Marso, Florian M M Baeres, Stephen C Bain, et al.
The Journal of Urology|April 20, 2013
SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-GuérinEila C Skinner, Bryan Goldman, Wael A Sakr, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2010
Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancerTanya B Dorff, Bryan Goldman, Jacek K Pinski, et al.
Clinical Genitourinary Cancer|October 1, 2008
Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanesTomasz M Beer, Bryan Goldman, Timothy W Synold, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2015
Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA StudiesJennifer L Kelly, Gilles Salles, Bryan Goldman, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
The Journal of Urology|April 18, 2009
A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219)Ralph W deVere White, Primo N Lara, Bryan Goldman, et al.
Diabetes, Obesity & Metabolism|September 13, 2021
Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight lossSean Wharton, Salvatore Calanna, Melanie Davies, et al.
Diabetes Care|November 26, 2025
Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS StudySilva Arslanian, Inge Gies, Bryan Goldman, et al.
Cancer|July 22, 2014
Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727)Philip A Philip, Bryan Goldman, Ramesh K Ramanathan, et al.
Obesity (Silver Spring, Md.)|May 23, 2020
Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5Robert F Kushner, Salvatore Calanna, Melanie Davies, et al.
Journal of the American College of Cardiology|March 14, 2020
Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart FailureSteven P Marso, Florian M M Baeres, Stephen C Bain, et al.
The Journal of Urology|April 20, 2013
SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-GuérinEila C Skinner, Bryan Goldman, Wael A Sakr, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2010
Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancerTanya B Dorff, Bryan Goldman, Jacek K Pinski, et al.
Clinical Genitourinary Cancer|October 1, 2008
Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanesTomasz M Beer, Bryan Goldman, Timothy W Synold, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2015
Low Serum Vitamin D Levels Are Associated With Inferior Survival in Follicular Lymphoma: A Prospective Evaluation in SWOG and LYSA StudiesJennifer L Kelly, Gilles Salles, Bryan Goldman, et al.
Pageof 4